767673--3/16/2006--SEROLOGICALS

related topics

{product, liability, claim}

{acquisition, growth, future}

{product, market, service}

{product, candidate, development}

{cost, contract, operation}

{property, intellectual, protect}

{customer, product, revenue}

{capital, credit, financial}

{personnel, key, retain}

{cost, regulation, environmental}

{operation, international, foreign}

{financial, litigation, operation}

If we are unable to implement our growth strategy, the price of our securities may be adversely affected. Loss of key management or key personnel could have a material adverse effect on our business. If we implement our growth strategy but are unable to manage our growth, our sales and profitability might be adversely affected. We may not be able to raise the additional capital necessary to implement our growth strategy. Our competitors may increase the sales of their products in a way that results in decreased sales of our products and our loss of market share. If our supply of bovine serum or recombinant human insulin were interrupted or if the price of such materials increases and we are unable to pass the increases to our customers, our Bioprocessing segment would be materially adversely affected. Concern about the transmission of BSE could reduce the demand for our cell culture products that are derived from bovine serum. We may incur costs in excess of amounts projected to close our manufacturing facilities in Toronto. We may lose sales as a result of our decision to close our manufacturing facilities in Toronto and not to open our manufacturing facility in Lawrence, Kansas. We may loose sales as a result of our decision to transfer certain manufacturing operations of our Research segment from Lake Placid, New York, to Temecula, California. The outsourcing trend in the pre-clinical and non-clinical stages of drug discovery and development may decrease, which could slow our growth. Violation of government regulations or voluntary quality programs could result in loss of sales and customers and additional expense to attain compliance. Our research and development efforts for new products may be unsuccessful. If we are not able to identify new licensing opportunities or to enter into licenses for new products on acceptable terms, we may be unable to offer new products, which would adversely affect our results of operations. If we fail to introduce new products, or our new products are not accepted by potential customers, we may lose market share. If we do not protect our intellectual property, our business could be materially adversely affected. Reduction or delays in research and development budgets and in government funding may negatively impact sales in our Research segment. We rely on international sales, which are subject to additional risks. Litigation may harm our business or otherwise distract our management. Compliance with environmental laws and regulations could adversely affect our results of operations. In both domestic and foreign markets, sales to our customers may depend, in part, on the availability of reimbursement from third-party payors. The sourcing, processing, manufacturing and sale of our products involve a risk of product and professional liability claims.

Full 10-K form ▸

767673--3/16/2006--SEROLOGICALS_CORP